Growth Hormone Increases Cortical and Cancellous Bone Mass in Young Growing Rats with Glucocorticoid-Induced Osteopenia
Open Access
- 1 May 1999
- journal article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 14 (5) , 710-721
- https://doi.org/10.1359/jbmr.1999.14.5.710
Abstract
The effects of growth hormone (GH) on linear growth, bone formation, and bone mass have been examined in glucocorticoid (GC)-injected young growing rats. Two-month-old female Wistar rats were injected for 90 days with 1, 3, 6, or 9 mg of methylprednisolone alone or in combination with 5 mg of GH. Bone mass and bone formation parameters were examined in the femoral cortical bone and in cortical bone and cancellous bone of the lumbar vertebra. GC administration dose dependently decreased growth, longitudinal growth of the vertebra, as well as the modeling drift of the cortical bone of the vertebral body and femoral diaphysis. In the vertebral cancellous bone, GC also decreased the mineralizing surface and inhibited the growth-related increase in cancellous bone volume. GH increased growth, longitudinal growth of the vertebra, as well as the modeling drift of the vertebral body and the femoral diaphysis, resulting in an increased cortical bone mass. GH also increased cancellous bone volume and the mineralizing surface of the vertebral body. In GC-injected animals, GH normalized and further increased growth, longitudinal growth, and the modeling drift of both the femoral diaphysis and the vertebral body, resulting in an increased cortical bone mass at both locations. GH also increased cancellous bone volume of the vertebral body in GC-injected animals, but GH did not, however, reverse the decreased mineralizing surface of cancellous bone induced by GC injections. In conclusion, GC administration to growing rats retards normal growth, longitudinal growth, and cortical bone modeling drift. It also decreases the cancellous bone mineralizing surface and inhibits the normal age-related increase in cancellous bone volume of the vertebral body. In the growing rat skeleton, GH can counteract these GC-induced side effects, except for the GC-induced decrease in the mineralizing surface of cancellous bone of the vertebral body, which remained unaffected by GH administration.Keywords
This publication has 33 references indexed in Scilit:
- Growth hormone administration can improve growth in glucocorticoid-injected rats without affecting the lymphocytopenic effect of the glucocorticoidGrowth Hormone & IGF Research, 1998
- Growth hormone treatment in growth-retarded adolescents after renal transplantThe Lancet, 1994
- Efficacy and safety of growth hormone treatment in short children with renal allografts: Three year experienceKidney International, 1993
- On the rat model of human osteopenias and osteoporosesBone and Mineral, 1992
- Short term linear growth in asthmatic children during treatment with prednisolone.BMJ, 1990
- Vertebral collapse in juvenile chronic arthritis: Its relationship with glucocorticoid therapyCalcified Tissue International, 1987
- Steroid-Induced Fractures and Bone Loss in Patients with AsthmaNew England Journal of Medicine, 1983
- Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosisMetabolic Bone Disease and Related Research, 1979
- Fractures in Still's DiseaseAnnals of the Rheumatic Diseases, 1960
- Effect of Cortisone on Growing Bones of the RatExperimental Biology and Medicine, 1951